Novartis Trial Suspensions to Have Limited Financial Impact
Dow Jones
6 hours ago
0815 GMT - Novartis's decision to suspend several clinical trials for a cell therapy after three patients died is expected to have a limited financial impact, Citi analysts say in a research note. Pending further updates, the news reduces the likelihood that the Swiss drugmaker's next-generation cell-therapy platform--which aims to accelerate the process of T-cell expansion to treat autoimmune diseases--could provide a future boost, the analysts say. However, the treatment was still in midstage trials, and Citi's current peak sales estimate stands at only $440 million. Novartis shares fall 0.6%.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.